Report on the 2017 NIH Regional Seminar
New Orleans, LA
May 3-5, 2017

Dr. Gina Clarkson, PhD, APRN, NNP-BC
Assistant Professor, School of Nursing
Acknowledgments

• Thank you to Dr. Rex Force
• Thank you to the Kasiska Division of Health Sciences
• Thank you to the School of Nursing; especially Dr. Nancy Renn and Dr. Karen Neill
Overview

• Main take-aways
  • Be sure to contact the NIH staff about your idea and where it fits.
  • Know which Program Official to contact and contact that person!

• Funding Opportunity Announcements
• RePORTER
• Loan Repayment Program
Program Official

- Responsible for the programmatic, scientific, and/or technical aspects of a grant
- Provides scientific guidance to investigators pre- and post-award
- Develops initiatives
- Provides post-award oversight
Funding Opportunity Announcement
Fundamentals
FOA- Funding Opportunity Announcement

- A publicly available document by which a Federal Agency makes known its intentions to award discretionary grants or cooperative agreements
- Includes all pertinent information and requirements for an applicant to assess their eligibility, competency, and interest in the funding opportunity
- Check out Grants.gov
If you have been impacted by natural disasters and are looking for more information, or to apply for assistance, please visit DisasterAssistance.gov.

Switch to Workspace Now
The Download Legacy PDF Application Package option to apply retires December 31, 2017. Apply using Grants.gov Workspace!

Get Started with Workspace »
www.nih.gov/grants-funding
Grants.nih.gov/grants/oer/htm
www.nih.gov/grants-funding
Find Funding for quick access to grant opportunities
Search “obesity”

Set search criteria.

View results tabs for FOAs and notices.

And try saving your search to receive email results in the future.
Types of FOA

- Requests for Applications (RFAs)
  - Solicit applications in a well-defined scientific area for specific program objectives. **Narrowly defined scope.**
  - Indicate the amount of set-aside funds and anticipated number of awards
  - Usually single receipt date

- Program Announcements (PAs)
  - Encourages applications for a new project. **Investigator initiated.**
  - Formerly termed “unsolicited” applications.
  - Usually ongoing (3 years). Often use standard receipt dates.
  - Parent Announcements - If no specific FOA for your area. Activity codes- R01, R03
Understanding Funding Opportunity Announcements
FOA ‘Glossary’

• Understanding options and requirements
  ○ Encouraged
  ○ Expected
  ○ Should
  ○ Must and Required

• SF424 (R&R)
<table>
<thead>
<tr>
<th>Participating Organization(s)</th>
<th>National Institutes of Health (NIH)</th>
</tr>
</thead>
</table>
| Components of Participating Organizations | National Institute of Allergy and Infectious Diseases (NIAID)  
NIMH  
NIH |
| Funding Opportunity Title | Innovative Measures of Oral Medication Adherence for HIV Treatment and Prevention (R01) |
| Activity Code | R01 Research Project Grant |
| Announcement Type | New |
| Related Notices | January 29, 2015 - Notice of Clarification of Funds Available and Anticipated Number of Awards for RFA-AI-14-071. See Notice NOT-AI-15-018 |
| Funding Opportunity Announcement (FOA) Number | RFA-AI-14-071 |
| Companion Funding Opportunity | None |
| Number of Applications | See Section III. 3. Additional Information on Eligibility. |
| Catalog of Federal Domestic Assistance (CFDA) Number(s) | 93.855; 93.856; 93.242 |
| Funding Opportunity Purpose | The purpose of this Funding Opportunity Announcement (FOA) is to solicit innovative research applications that seek to advance the development of bioanalytical assays, pill ingestion sensors, drug metabolite and taggant detection systems, or wireless technologic approaches for monitoring and improving adherence to oral antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP). |
## Part 1. Key Dates

<table>
<thead>
<tr>
<th><strong>Posted Date</strong></th>
<th>November 26, 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Open Date (Earliest Submission Date)</strong></td>
<td>February 25, 2015</td>
</tr>
<tr>
<td><strong>Letter of Intent Due Date(s)</strong></td>
<td>February 25, 2015</td>
</tr>
<tr>
<td><strong>Application Due Date(s)</strong></td>
<td>March 25, 2015, by 5:00 PM local time of applicant organization. All <a href="#">types of non-AIDS applications</a> allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.</td>
</tr>
<tr>
<td><strong>AIDS Application Due Date(s)</strong></td>
<td>March 25, 2015, by 5:00 PM local time of applicant organization. All <a href="#">types of AIDS and AIDS-related applications</a> allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.</td>
</tr>
<tr>
<td><strong>Scientific Merit Review</strong></td>
<td>July 2015</td>
</tr>
<tr>
<td><strong>Advisory Council Review</strong></td>
<td>October 2015</td>
</tr>
<tr>
<td><strong>Earliest Start Date</strong></td>
<td>December 2015</td>
</tr>
<tr>
<td><strong>Expiration Date</strong></td>
<td>March 26, 2015</td>
</tr>
<tr>
<td><strong>Due Dates for E.O. 12372</strong></td>
<td>Not Applicable</td>
</tr>
</tbody>
</table>
Part 2. Section I
Funding Opportunity Description

• **Purpose:** Goals of the funding opportunity

• **Background:** Relevant background information and the importance of the funding opportunity

• **Research Objectives:** Description of specific areas of research interest; examples of targeted research topics and/or and experimental approaches that are being sought to achieve the objectives.

• **Specific Areas of Research Interest**
| Part 2. Section II  
Award Information |
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Funding Instrument</strong></td>
</tr>
</tbody>
</table>
| **Application Types Allowed** | New  
  The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. |
| **Funds Available and Anticipated Number of Awards** | Issuing IC and partner component intend to commit an estimated total of $7 million to fund 6-8 awards. |
| **Award Budget** | Application budgets are not limited but need to reflect the actual needs of the proposed project. |
| **Award Project Period** | The scope of the proposed project should determine the project period. The project period can be 3-5 years. |
Part 2. Section III
Eligibility Information

• Eligible institutions
  o Application is submitted by institution- Cayuse

• Eligible individuals
  o Only applicable for PD/PI
  o Multiple PD/PI applications: Eligibility requirements apply to all PD/PIs

• Number of applications
  o Usually only limited to avoid duplicate or highly overlapping applications
Letters of Intent

- Requested in some FOAs to help with planning the review
- Not required; does not impact review

**Letter of Intent**

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1, Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

- Descriptive title of proposed activity
- Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
- Names of other key personnel
- Participating institution(s)
- Number and title of this funding opportunity
Instructions for Application Submission

- Lists of all the forms available in the application package
- Instructs applicant to follow instructions in the SF 424 (R&R) Application Guide in addition to FOA-specific instructions
- An applicant should be able to prepare an application by reading the SF 424 (R&R) Application Guide and this section only
Part 2. Section V
Application Review Information

• Review criteria- “The Grant Application Writer’s Workbook”
  o Significance
  o Investigator(s)
  o Innovation
  o Approach
  o Environment

• Review and selection process
  o peer review process
  o funding decisions
Part 2. Section VI
Award Administration Information

• Award Notices
• Reporting requirements
Part 2. Section VII
Agency Contacts

• FOA-specific Contacts
  - Scientific/Research
  - Peer Review
  - Financial/Grants Management
NIH Online Report Tool - RePORT
What do I use RePORT for?

- Award trends
- Which IC (Institute and Center) funds research like yours?
- Determine which NIH study sections review applications in specific fields
- What projects have been done that are similar to yours? 25 years of data available!
- To find other NIH grantees in my area
- Potential collaborators
- Success rates
- NIH staff contacts
- NIH “Big Picture” and strategic plans
- Keep in mind that the default is for Active projects
My take aways

• Matchmaker shows 100 most similar projects

• Communicating and acknowledging federal funding shows how to cite your grant.

• Abstracts provided to NIH for funded grants are for congressional staff/others who want to know what NIH is funding. Don’t use ‘edgy’ titles.

• My RePORTER saves searches and can send notifications
Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery.
You can start search in “search’ bar or you can click on RePORT.
Let’s search to learn who and what NIH funds on obesity
Active Projects is the default
5034 active projects... yikes!

How to understand our result?
Try the Data and Visualize tab
Now it is more clear which ICs fund obesity research!
Circles helps visualize specific scientific areas

<table>
<thead>
<tr>
<th>Project ID</th>
<th>Project Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>5R01DK98520-02</td>
<td>BRAIN INTEREPIGENIC CONTROL OF FOOD INTAKE AND ENERGY EXPENDITURE</td>
</tr>
<tr>
<td>5R01DK98293-01A1</td>
<td>TRAINING EFFECTS ON SKELETAL MUSCLE LIPODYNAMICS</td>
</tr>
<tr>
<td>1ZIAAG000315-13</td>
<td>DETERMINATION OF BRAIN AGING AND NEURODEGENERATIVE DISEASES</td>
</tr>
<tr>
<td>5R01DK98507-02</td>
<td>REDOX BIOLOGY AND MUSCLE INSULIN SENSITIVITY</td>
</tr>
<tr>
<td>5R01HL116572-01</td>
<td>RESISTANCE AND CARDIORESPIRATORY FITNESS IN YOUTH: A RANDO</td>
</tr>
<tr>
<td>5R01DK98083-02</td>
<td>INSULIN SENSITIVITY IN A NOVEL MOUSE MODEL OF CR STRESS</td>
</tr>
<tr>
<td>5R01DK98773-10</td>
<td>REGULATION OF HEPATIC LIPOID AND GLUCOSE METABOLISM BY ACTIVATION</td>
</tr>
<tr>
<td>5O10DK98558-03</td>
<td>MECHANISMS OF DIETARY LIPOID MODULATION OF INSULIN RESISTANCE</td>
</tr>
<tr>
<td>5R01DK98521-02</td>
<td>VISCERAL ADIPOSE TISSUE AS MEDIATOR BETWEEN LIFESTYLE FACTORS AND CARDIOMETABOLIC RISK FACTORS</td>
</tr>
<tr>
<td>5R01DK98264-02</td>
<td>STIMULATED BY BETA 3 IN ENERGY HOMEOSTASIS</td>
</tr>
<tr>
<td>5R01DK98547-01S1</td>
<td>EFFECT OF BARiatric SURGERY ON MECHANISMS OF TYPE 2 DIABETES: THE BW TRIAL</td>
</tr>
<tr>
<td>5R01DK98349-01S1</td>
<td>MECHANISTIC STUDY OF A FASN GENE MUTATION THAT CAUSES LIPODYSTROPHY &amp; DIABETES</td>
</tr>
<tr>
<td>5R01DK98740-05</td>
<td>INSULIN SENSITIVITY AND FATTY ACID PARTITIONING IN SKELETAL MUSCLE AFTER EXERCISE</td>
</tr>
<tr>
<td>5R01HL112692-02</td>
<td>VITAMIN D AND VASCULAR FUNCTION IN OBESITY CHILDREN</td>
</tr>
<tr>
<td>5R01HL111728-05</td>
<td>MITOCHONDRIAL FUNCTION AND ADIPOSE INSULIN SENSITIVITY</td>
</tr>
<tr>
<td>5R01DK98344-02</td>
<td>ANTENATAL STEROIDS AND CARDIORESPIRATORY RISK FACTORS</td>
</tr>
<tr>
<td>5R01DK98388-02</td>
<td>MITOCHONDRIAL DYSFUNCTION AND ADIPOSE INSULIN SENSITIVITY</td>
</tr>
</tbody>
</table>
Hypothalamic neurons expressing Agouti-related peptide (AgRP) are critical for initiating food intake, but druggable biochemical pathways that control this response remain elusive. Thus, genetic ablation of insulin or leptin signaling in AgRP neurons is predicted to reduce satiety but fails to do so. FoxO1 is a shared mediator of both pathways, and its inhibition is required to induce satiety. Accordingly, FoxO1 ablation in AgRP neurons of mice results in reduced food intake, leanness, improved glucose homeostasis, and increased sensitivity to insulin and leptin. Expression profiling of flow-sorted FoxO1-deficient AgRP neurons identifies G-protein-coupled receptor Gpr17 as a FoxO1 target whose expression is regulated by nutritional status. Intracerebroventricular injection of Gpr17 agonists induces food intake, whereas Gpr17 antagonist cangrelor curtails it. These effects are absent in Agrp-Foxo1 knockouts, suggesting that pharmacological modulation of this pathway has therapeutic potential to treat obesity.
Delving back into individual projects...
Details tab provides PI contact info and profile (if this is you, add profile info by clicking on icon)

NIH program official for this grant

FOA

Review panel
Use Nearby Projects tab to locate others who may be working locally on your topic of interest.
How much funding in my state and congressional district?

What types of organizations does NIH fund?

Who has NIH funding in my university system?
 NIH Awards in Idaho

Funding

NIH Awards by Location & Organization

Explore year-by-year NIH funding by institution, state, congressional district, and more! Data as of 10/12/2017. Frozen FY 2017 data are planned for release by 31 December 2017. These data will include R&D contracts, fellowships, other grant awards not yet past their budget start date.

Fiscal Year: 2017
Institute/Center: All
Funding Mechanism: All
FOA: All

By Organization

<table>
<thead>
<tr>
<th>Organization</th>
<th>City</th>
<th>State</th>
<th>Country</th>
<th>Awards</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNIVERSITY OF IDAHO</td>
<td>MOSCOW</td>
<td>ID</td>
<td>UNITED STATES</td>
<td>9</td>
<td>$7,304,292</td>
</tr>
<tr>
<td>BOISE STATE UNIVERSITY</td>
<td>BOISE</td>
<td>ID</td>
<td>UNITED STATES</td>
<td>7</td>
<td>$3,839,897</td>
</tr>
<tr>
<td>CARING TECHNOLOGIES, INC.</td>
<td>BOISE</td>
<td>ID</td>
<td>UNITED STATES</td>
<td>2</td>
<td>$565,191</td>
</tr>
<tr>
<td>PRIMAL THERAPIES, INC.</td>
<td>BOISE</td>
<td>ID</td>
<td>UNITED STATES</td>
<td>1</td>
<td>$206,479</td>
</tr>
<tr>
<td>IDAHO VETERANS RESEARCH / EDUCATION FDN</td>
<td>BOISE</td>
<td>ID</td>
<td>UNITED STATES</td>
<td>1</td>
<td>$1,891,500</td>
</tr>
<tr>
<td>IDAHO STATE UNIVERSITY</td>
<td>POCATELLO</td>
<td>ID</td>
<td>UNITED STATES</td>
<td>1</td>
<td>$193,034</td>
</tr>
<tr>
<td>Project Number</td>
<td>Project</td>
<td>Organization</td>
<td>Admin IC</td>
<td>Direct Cost</td>
<td>Indirect Cost</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>----------</td>
<td>--------------</td>
<td>---------------</td>
</tr>
<tr>
<td>7R01GM106156-05</td>
<td>Autoregressive Signal Amputation</td>
<td>BOISE STATE UNIVERSITY</td>
<td>NIGMS</td>
<td>$190,000</td>
<td>$75,950</td>
</tr>
<tr>
<td>5P20GM106265-04</td>
<td>Center of Biomedical Research</td>
<td>BOISE STATE UNIVERSITY</td>
<td>NIGMS</td>
<td>$1,436,317</td>
<td>$547,656</td>
</tr>
<tr>
<td>1R15GM106252-02</td>
<td>Identification and Characterization of an Integrin - Notch Signaling</td>
<td>BOISE STATE UNIVERSITY</td>
<td>NIGMS</td>
<td>$299,550</td>
<td>$114,025</td>
</tr>
<tr>
<td>1R15GM106252-02</td>
<td>Development of New Antifungal Agents to Treat Protozoan Parasites</td>
<td>BOISE STATE UNIVERSITY</td>
<td>NIGMS</td>
<td>$390,000</td>
<td>$117,731</td>
</tr>
<tr>
<td>1R25GM106252-02</td>
<td>The Southwest Marine Bridge to the Pacific Ocean</td>
<td>BOISE STATE UNIVERSITY</td>
<td>NIGMS</td>
<td>$214,745</td>
<td>$114,152</td>
</tr>
<tr>
<td>1R15GM106252-02</td>
<td>Spatiotemporal Dynamics of Transmission and Spreading by True</td>
<td>BOISE STATE UNIVERSITY</td>
<td>NIGMS</td>
<td>$299,992</td>
<td>$110,162</td>
</tr>
<tr>
<td>1R15GM106252-02</td>
<td>Pathogens Disease by VPHIS</td>
<td>BOISE STATE UNIVERSITY</td>
<td>NIMH</td>
<td>$91,127</td>
<td>$27,460</td>
</tr>
<tr>
<td>5R44MH112476-02</td>
<td>Accelerating the diagnosis of Autism Spectrum disorder in rural</td>
<td>CARING TECHNOLOGIES, INC</td>
<td>NIMH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3R44MH112476-02</td>
<td>Autism spectrum disorder in rural Idaho via evidence-based</td>
<td>CARING TECHNOLOGIES, INC</td>
<td>NIMH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5R44AA020364-05</td>
<td>Sleep, Physiology and Risk for</td>
<td>IDAHO STATE UNIVERSITY</td>
<td>NIAAA</td>
<td>$175,820</td>
<td>$17,105</td>
</tr>
<tr>
<td>5R44AA020364-05</td>
<td>Sleep, Physiology and Risk for</td>
<td>BOISE STATE UNIVERSITY</td>
<td>NIMH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5P20GM106252-02</td>
<td>Collaborative in Emerging Infectious Diseases</td>
<td>IDAHO VETERANS RESEARCH/EDUCATION FDN</td>
<td>NIMH</td>
<td>$1,500,000</td>
<td>$391,500</td>
</tr>
<tr>
<td>1R15AG065626-01</td>
<td>Evaluation of daily oral care</td>
<td>PRIMAL THERAPIES, INC.</td>
<td>NIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5R44GM102324-05</td>
<td>Phase II; Translational Research on Processes in Evolution</td>
<td>UNIVERSITY OF IDAHO</td>
<td>NIGMS</td>
<td>$708,745</td>
<td>$231,453</td>
</tr>
<tr>
<td>1R01CA161788-01</td>
<td>Treating Viruses for Cancer Therapy</td>
<td>UNIVERSITY OF IDAHO</td>
<td>NCI</td>
<td>$50,000</td>
<td>$19,748</td>
</tr>
<tr>
<td>1R21EO106269-01</td>
<td>Off-Label, Non-Receptor Based and Novel</td>
<td>UNIVERSITY OF IDAHO</td>
<td>NEI</td>
<td>$150,098</td>
<td>$40,518</td>
</tr>
<tr>
<td>1R21EO106269-01</td>
<td>Off-Label, Non-Receptor Based and Novel</td>
<td>UNIVERSITY OF IDAHO</td>
<td>NEI</td>
<td>$155,000</td>
<td>$35,525</td>
</tr>
<tr>
<td>1R21EO106269-01</td>
<td>Syntheses in Receptors Region</td>
<td>UNIVERSITY OF IDAHO</td>
<td>NEI</td>
<td>$125,000</td>
<td>$60,626</td>
</tr>
<tr>
<td>5R01CA122679-02</td>
<td>COLLABORATIVE RESEARCH on Mathematical Theory of Transmissible</td>
<td>UNIVERSITY OF IDAHO</td>
<td>NIMHS</td>
<td>$194,655</td>
<td>$57,754</td>
</tr>
</tbody>
</table>
ISU NIH grant’s Project Information

Project Information

Project Number: SR01AA020364-05
Former Number: SR01AA020364-04
Title: SLEEP PHYSIOLOGY AND RISK FOR ALCOHOL PROBLEMS IN CHILDREN OF ALCOHOLICS

Contact PI / Project Leader Information:
- Name: WONG, MARIA M.
- Email: Click to view Contact PI / Project Leader email address

Program Official Information:
- Name: REGUNATHAN, SOUNDR
- Email: Click to view PO email address

Organization:
- IDAHO STATE UNIVERSITY
- PSYCHOLOGY
- SCHOOLS OF ARTS AND SCIENCES

Administrating Institutes or Centers:
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

Project Funding Information for 2017:
- Total Funding: $193,934
- Direct Costs: $176,625
- Indirect Costs: $17,105

Download Readers:
Projectreporter.nih.gov/reporter.cfm
Use ExPORTER to get the data to do your own detailed analysis.
Do I Contact NIH *Before* Applying?

Yes!

**Mandatory**
- Application with budget $\geq 500,000$ direct costs for any single year
- R13 Conference Grants

**Always Recommended**
- When you think about applying for *any* grant
Finding the Right Staff Contacts

- **FOAs** include contact names for program, review and grants management staff.

- **Institute websites** have org charts or contact lists so to help you find a name. [www.nih.gov](http://www.nih.gov)

- **RePORTER** provides the NIH program official’s name for funded projects. [projectreporter.nih.gov](http://projectreporter.nih.gov)

- Use the **NIH Staff Directory** if you already have a name [ned.nih.gov](http://ned.nih.gov)

- If in doubt, use the help link on grants.nih.gov for guidance.
Loan Repayment Program
About the LRPs

NIH Loan Repayment Programs (LRPs) are a **vital component** in our nation's effort to keep health professionals in research careers.

*Here’s how it works:* 

**YOU:** Commit to perform research for 2 years

**NIH:** Repays up to **$35,000/year** of your qualified educational debt **and** covers resulting Federal taxes (39%)

**Outcome:** Increase in nation’s stock of biomedical research scientists
Basic LRP Eligibility Criteria

**Doctoral Degree**
M.D., Ph.D., or equivalent
Exception: Contraception & Infertility Research LRP

**Research Funding**
Domestic nonprofit, university, or government organization; NIH grant support NOT required

**Citizenship**
U.S. Citizen or permanent resident

**Educational Loan Debt**
At least 20% of applicant's annual income

**Research Time**
At least 20 hours/week
Qualifying Loans

**NIH WILL Repay:**
- Educational loans backed by the U.S. government
- Educational loans from accredited U.S. academic institutions and commercial lenders

**NIH Will NOT Repay:**
- Non-educational loans (e.g. home equity loans)
- PLUS loans to parents
  - **EXCEPTION:** PLUS loans disbursed to graduate and professional students on or after July 1, 2006, qualify for LRP repayment
- Loans from non-US governments or institutions
- Loans converted to a service obligation, delinquent or in default
- Loans consolidated with another individual (e.g. spouse or child)
- Loans of full-time Federal government employees or VA Fellows
What Are Reviewers Looking For?

Reviewers evaluate applicant’s potential to succeed in a research career by rating:

- Applicant’s previous training and research experience
- Applicant’s commitment to a research career
- Strength and quality of letters of recommendation
- Quality and appropriateness of the research environment
- Research progress (for Renewal applications only)
- Publications!!
- Need to be funded!!
Summary - Application period 9/1 to 11/15

• **5 Extramural LRPs**
• **eRA Commons ID Required**
• **NIH LRPs will repay:**
  o Up to **$70K over 2 yrs** in educational loan repayment
    • Depending on debt level
  o Coverage of most Federal taxes resulting from the NIH LRP
  o 2 year initial contracts
    • 1 or 2 year competitive renewals
  o Approximately **1,600 researchers funded yearly**
  o **50% application success rate overall**
Thank you for coming!

Questions?